# Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

> **NCT02939846** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02939846
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05
- **Primary completion:** 2018-08
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in strategy
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939846, "Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02939846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*